Loading clinical trials...
Loading clinical trials...
The Effects of Oral Nanocurcumin on Expression Levels of microRNAs and Treg Cells and Th17 Cells Development Factors in Multiple Sclerosis Patients
Conditions
Interventions
Nanocurcumin
Placebo
Locations
1
Iran
Drug Applied Research Center, Tabriz, Iran
Tabriz, Iran
Start Date
June 8, 2016
Primary Completion Date
August 10, 2017
Completion Date
November 7, 2017
Last Updated
September 17, 2018
NCT07225504
NCT06276634
NCT06809192
NCT05359653
NCT07376772
NCT07426991
Lead Sponsor
Tabriz University of Medical Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions